By Professor Yong Li

Journal articles

Li Y; Cozzi PJ, 2010, 'Angiogenesis as a strategic target for prostate cancer therapy', Medicinal Research Reviews, 30, pp. 23 - 66, http://dx.doi.org/10.1002/med.20161

Hao JL; Cozzi PJ; Khatri A; Power CA; Li Y, 2010, 'CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer', Current Cancer Drug Targets, 10, pp. 287 - 306

Hao JL; Chen H; Madigan MC; Cozzi PJ; Beretov J; Xiao W; Delprado W; Russell PJ; Li Y, 2010, 'Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.', British Journal of Cancer, 103, pp. 1008 - 1018, http://dx.doi.org/10.1038/sj.bjc.6605839

Chen H; Wang L; Beretov J; Hao J; Xiao W; Li Y, 2010, 'Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression', Clinical and Experimental Metastasis, 27, pp. 557 - 569, http://dx.doi.org/10.1007/s10585-010-9345-9

Chen H; Wang L; Beretov J; Xiao W; Li YH; Hao J, 2010, 'Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression', Clinical and Experimental Metastasis, 27, pp. 557 - 569, http://dx.doi.org/10.1007/s10585-010-9345-9

You J; Cozzi PJ; Walsh B; Willcox MD; Kearsley J; Russell PJ; Li Y, 2010, 'Innovative biomarkers for prostate cancer early diagnosis and progression', Critical Reviews in Oncology Hematology, 73, pp. 10 - 22, http://dx.doi.org/10.1016/j.critrevonc.2009.02.007

You J; Fitzgerald A; Cozzi PJ; Zhao Z; Graham PH; Russell PJ; Walsh B; Willcox MD; Ling Z; Wasinger VC; Li Y, 2010, 'Post-translation modification of proteins in tears', Electrophoresis, 31, pp. 1853 - 1861, http://dx.doi.org/10.1002/elps.200900755

You J; Fitzgerald A; Cozzi PJ; Zhao Z; Graham P; Russell PJ; Walsh BJ; Willcox M; Zhong L; Wasinger V; Li Y, 2010, 'Post‐translation modification of proteins in tears', PROTEOMICS – Clinical Applications, 4, pp. 870 - 870, http://dx.doi.org/10.1002/prca.201090087

Li Y; Cozzi PJ; Russell P, 2010, 'Promising tumor-associated antigens for future prostate cancer therapy', Medicinal Research Reviews, 30, pp. 67 - 101

Madigan M; Kingsley E; Paul C; Delprado W; Russell P; Li Y, 2009, 'The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression', CLINICAL & EXPERIMENTAL METASTASIS, 26, pp. 898 - 898, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000271722300160&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chen H; Hao J; Wang L; Li Y, 2009, 'Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression', British Journal of Cancer, 101, pp. 432 - 440

Wang LL; Madigan MC; Chen H; Liu F; Patterson K; Beretov J; O Brien P; Li Y, 2009, 'Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients', Gynecologic Oncology, 114, pp. 265 - 272

Li Y; Song YE; Rizvi SM; Power C; Beretov J; Raja C; Cozzi PJ; Morgenstern A; Apostolidis C; Allen BJ; Russell PJ, 2009, 'Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By (213)Bilabeled Multiple Targeted alpha Radioimmunoconjugates', Clinical Cancer Research, 15, pp. 865 - 875, http://dx.doi.org/10.1158/1078-0432.CCR-08-1203

Kearsley J; Cozzi PJ; Li Y, 2008, 'Overview of Tumor-Associated Antigens (TAAs) as potential Therapeutic Targets for prostate Cancer Therapy', Current Cancer Therapy Reviews, 4, pp. 271 - 284

Rizvi SM; Qu CF; Raja C; Yuen J; Li Y; Morgenstern A; Apostolidis C; Allen BJ; Song YE, 2008, 'The cytokinesis-block micronucleus assay as a biological dosimeter for targeted alpha therapy', Physics in Medicine and Biology, 53, pp. 319 - 328, http://dx.doi.org/10.1088/0031-9155/53/2/001

Madigan MC; Kingsley EA; Cozzi PJ; Delprado W; Russell PJ; Li Y, 2008, 'The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression', Cancer Immunology and Immunotherapy, 57, pp. 1367 - 1379

Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins A; Li Y, 2007, 'Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance', Gynecologic Oncology, 105, pp. 695 - 702

Li Y; Cozzi PJ, 2007, 'MUC1 is a promising therapeutic target for prostate cancer therapy', Current Cancer Drug Targets, 7, pp. 259 - 271

Allen B; Raja C; Rizvi S; Song E; Li Y; Graham P; Kearsley J; Thompson J; Morgenstern A; Apostolidis C; Reisfeld R, 2007, 'P-16 Regression of melanoma by tumour anti-vascular alpha therapy', Melanoma Research, 17, pp. A24 - A24, http://dx.doi.org/10.1097/00008390-200702000-00062

Li Y; Cozzi PJ, 2007, 'Targeting uPA/uPAR in prostate cancer', Cancer Treatment Reviews, 33, pp. 521 - 527

Wang JQ; Abbas Rizvi SM; Madigan MC; Cozzi PJ; Morgenstern A; Qu CF; Apostolidis C; Russell PJ; Allen BJ; Li Y, 2006, 'Control of prostate cancer spheroid growth using (213)Bi-labeled multiple targeted alpha radioimmunoconjugates', Prostate, 66, pp. 1753 - 1767

Wang J; Rizvi SM; Madigan MC; Cozzi PJ; Power C; Qu CF; Morgenstern A; Apostolidis C; Russell PJ; Allen BJ; Li Y, 2006, 'Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates.', Prostate, 66, pp. 1753 - 1767

Song YE; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins A; Allen BJ, 2006, 'Cytoxicity of PA12, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters', Cancer Letters, 234, pp. 176 - 183

Cozzi PJ; Wang JQ; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y, 2006, 'Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer', Human Pathology, 37, pp. 1442 - 1451

Rizvi SM; Li Y; Song YE; Qu CF; Raja C; Morgenstern A; Apostollidis C; Allen BJ, 2006, 'Preclinical studies of Bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model', Cancer Biology and Therapy, 5, pp. 386 - 393

Nielsen A; Scarlett CJ; Samra JS; Gill A; Li Y; Allen BJ; Smith RC, 2005, 'Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 20, pp. 256 - 263, http://dx.doi.org/10.1111/j.1440-1746.2004.03531.x

Qu CF; Songl YJ; Rizvi SMA; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ, 2005, 'In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.', Cancer biology & therapy, 4, pp. 848 - 853, http://dx.doi.org/10.4161/cbt.4.8.1892

Nielsen A; Scarlett CJ; Samra JS; Gill A; Li Y; Allen BJ; Smith RC, 2005, 'Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction', Journal of Gastroenterology and Hepatology (Australia), 20, pp. 256 - 263, http://dx.doi.org/10.1111/j.1440-1746.2004.03531.x

Zhang D; Li Y; Rizvi SM; Qu CF; Kearsley J; Allen BJ, 2005, 'Cytotoxicity of breast cancer cells overexpressing HER2/neu by(213)Bi-Herceptin radioimmunoconjugate', Cancer Letters, 218, pp. 181 - 190

Cozzi PJ; Rizvi SM; Wang J; Qu CF; Allen BJ; Li Y, 2005, 'Expression of membrane-bound uPA in human prostate cancer cells for in vitro and in vivo targeted alpha therapy using 213Bi-PAI2 alpha emitting radioconjugate', British Journal of Urology, 95, pp. 16 - 17

Li Y; Wang JQ; Rizvi SM; Conway RM; Billson FA; Allen BJ; Madigan MC, 2005, 'In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells', Investigative Ophthalmology and Visual Science, 46, pp. 4365 - 4371

Qu CF; Song YE; Rizvi SM; Li Y; Smith RC; Perkins A; Morgenstern A; Brechbiel M; Allen BJ, 2005, 'In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using Bi-213-CHX.A`-C595', Cancer Biology and Therapy, 4, pp. 848 - 853

Allen BJ; Raja C; Rizvi SM; Tsui WW; Li Y; Graham PH; Thompson J; Reisfeld RA; Kearsley J; Morgenstern A; Apostolidis C, 2005, 'Intralesional targeted alpha therapy for metastatic melanoma', Cancer Biology and Therapy, 4, pp. 1318 - 1324

Cozzi PJ; Wang J; Delprado W; Perkins A; Allen BJ; Russell PJ; Li Y, 2005, 'MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer', Clinical and Experimental Metastasis, 22, pp. 565 - 573

Qu CF; Li Y; Rizvi SM; Raja C; Smith RC; Morgenstern A; Apostolidis C; Allen BJ; Song YE, 2005, 'Pre-clinical study of Bi-213 labeled PAI2 for the control of micrometastatic pancreatic cancer', Clinical and Experimental Metastasis, 22, pp. 575 - 586

Li Y; Rizvi SM; Blair JM; Cozzi PJ; Chang QF; Kim OT; Tam P; Perkins A; Russell PJ; Allen BJ, 2004, 'Antigenic Expression of Human Metastatic Prostate Cancer Cell Lines for In Vitro Multiple-Targetes A-Therapy with 21Bi-Conjugates', International Journal of Radiation Oncology and Biology Physics, 60, pp. 896 - 908

Li Y; Russell PJ; Allen BJ, 2004, 'Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate', Cancer Letters, 205, pp. 161 - 171

Russell PJ; Ow KT; Tam P; Juarez J; Kingsley EA; Li Y; Cozzi PJ; Qu CF; Martiniello-Wilks R, 2004, 'Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer', Cancer Immunology and Immunotherapy, 53, pp. 995 - 1004

Qu CF; Song YE; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins A; Apostolidis C; Allen BJ, 2004, 'MUC-1 expression in primary and metastatic [ancreatic cancer cells for in vitro treatment by 213 Bi-C595 radioimmunoconjugate', British Journal of Cancer, 91, pp. 2086 - 2093

Allen BJ; Raja C; Rizvi SM; Li Y; Tsui WW; Zhang DY; Song YE; Qu CF; Kearsley J; Graham PH; Thompson J, 2004, 'Targeted alpha therapy for cancer', Physics in Medicine and Biology, 49, pp. 3703 - 3712

Li Y; Russell PJ; Allen BJ, 2004, 'Targeted alpha-therapy for control of micrometastatic prostate cancer', Expert Review of Anticancer Therapy, 4, pp. 459 - 468, http://www.sciencedirect.com/science/article/B6WVB-4CGGB79-1Y2/2/78aed94232955f13edd392636a9f091a

Allen BJ; Tian Z; Rizvi SMA; Li Y; Ranson M, 2003, 'Preclinical studies of targeted α therapy for breast cancer using ²¹³Bi-labelled-plasminogen activator inhibitor type 2', British Journal of Cancer, 88, pp. 944 - 950, http://dx.doi.org/10.1038/sj.bjc.6600838

Rizvi SM; Li Y; Raja C; Allen BJ, 2003, 'In vitro and preclinical testing of Bi-213 labeled antimelanoma monoclonal antibody 9.2.27', Abstracts of Papers of the American Chemical Society, 225, pp. U261 - U261, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000187918001337&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Li L; Li Y; Krilis S; Qi JC; Moore CH; Madigan MC; Katsoulotos GP, 2003, 'An antibody raised against in-vitro-derived human mast cells identifies mature mast cells and a population of cells that are Fc...., Tryptase, and chymase in a variety of human tissues', Journal of Histochemistry and Cytochemistry, 51, pp. 643 - 653

Li Y; Madigan MC; Conway RM; Billson FA; Crouch RL; Allen BJ, 2003, 'Human uveal melanoma expresses NG2 immunoreactivity', British Journal of Ophthalmology, 87, pp. 629 - 632

Li Y; Rizvi SMA; Ranson M; Allen BJ, 2002, 'Bi-213-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model', BRITISH JOURNAL OF CANCER, 86, pp. 1197 - 1203, http://dx.doi.org/10.1038/sj/bjc/6600179

Li Y; Tian Z; Rizvi SMA; Bander NH; Allen BJ, 2002, 'In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen', Prostate Cancer and Prostatic Diseases, 5, pp. 36 - 46, http://dx.doi.org/10.1038/sj.pcan.4500543

Allen BJ; Tian Z; Li Y; Andronicos NJ; Rizvi S; Ranson M, 2001, 'In vitro and preclinical studies of targeted alpha therapy for human breast cancer using 213Bi-labeled-plasminogen activator inhibitor type 2', EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 28, pp. 1191 - 1191, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000170528300888&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M, 2001, 'In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers', Critical Reviews in Oncology/Hematology, 39, pp. 139 - 146, http://dx.doi.org/10.1016/S1040-8428(01)00113-5

Li Y; Li L; Wadley RB; Reddel SW; Qi JC; Archis CA; Collins AM; Clarke E; Cooley MA; Kouts S; Naif H; Alali M; Cunningham AL; Wong GW; Stevens RL; Krilis S, 2001, 'Mast cell/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5 and CXCR4', Blood, pp. 3484 - 3490

Back to profile page